Multiple Sclerosis Journal, 1477-0970

Journal

More filtering options
  1. 2021
  2. Leptin levels are associated with multiple sclerosis risk

    Martin Biström, Johan Hultdin, Oluf Andersen, Lucia Alonso-Magdalena, Daniel Jons, Martin Gunnarsson, Magnus Vrethem & Peter Sundström, 2021, In: Multiple Sclerosis Journal. 27, 1, p. 19-27

    Research output: Contribution to journalArticle

  3. 2018
  4. Male factor infertility and risk of multiple sclerosis: A register-based cohort study

    Clara Helene Glazer, Sandra Søgaard Tøttenborg, Aleksander Giwercman, Elvira Vaclavik Bräuner, Michael L. Eisenberg, Ditte Vassard, Melinda Magyari, Anja Pinborg, Lone Schmidt & Jens Peter Bonde, 2018 Dec, In: Multiple Sclerosis Journal. 24, 14, p. 1835-1842

    Research output: Contribution to journalArticle

  5. 2016
  6. Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study

    Katalin T. Kovacs, Sudhakar Reddy Kalluri, Antonio Boza-Serrano, Tomas Deierborg, Tunde Csepany, Magdolna Simo, Laszlo Rokusz, Attila Miseta, Nicolas Alcaraz, Laszlo Czirjak, Timea Berki, Tihamer Molnar, Bernhard Hemmer & Zsolt Illes, 2016 Aug 1, In: Multiple Sclerosis Journal. 22, 9, p. 1192-1201 10 p.

    Research output: Contribution to journalArticle

  7. 2015
  8. Cell-specific effects in different immune subsets associated with SOCS1 genotypes in multiple sclerosis

    Aitzkoa Lopez de Lapuente, María Jesús Pinto-Medel, Ianire Astobiza, Iraide Alloza, Manuel Comabella, Sunny Malhotra, Xavier Montalban, Uwe K Zettl, Alfredo Rodríguez-Antigüedad, Oscar Fernández & Koen Vandenbroeck, 2015 Oct, In: Multiple Sclerosis Journal. 21, 12, p. 1498-512

    Research output: Contribution to journalArticle

  9. 2013
  10. Cerebrospinal fluid oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald criteria 2010: Yes.

    Magnhild Sandberg Wollheim & Tomas Olsson, 2013, In: Multiple Sclerosis Journal. 19, 6, p. 714-716

    Research output: Contribution to journalDebate/Note/Editorial

  11. 2012
  12. Cost of multiple sclerosis in the Czech Republic: The COMS study

    J. Blahova Dusankova, T. Kalincik, T. Dolezal, Gisela Kobelt & E. Havrdova, 2012, In: Multiple Sclerosis Journal. 18, 5, p. 662-668

    Research output: Contribution to journalArticle

  13. 2011
  14. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis

    Carolina Holmen, Fredrik Piehl, Jan Hillert, Anna Fogdell-Hahn, Malin Lundkvist, Elin Karlberg, Petra Nilsson, Charlotte Dahle, Nils Feltelius, Anders Svenningsson, Jan Lycke & Tomas Olsson, 2011, In: Multiple Sclerosis Journal. 17, 6, p. 708-719

    Research output: Contribution to journalArticle

  15. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a Therapy.

    Magnhild Sandberg Wollheim, Enrica Alteri, Margaretha Stam Moraga & Gabrielle Kornmann, 2011, In: Multiple Sclerosis Journal. 17, 4, p. 423-430

    Research output: Contribution to journalArticle

  16. The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-1a: analysis of data from clinical trial and post-marketing surveillance settings.

    Magnhild Sandberg Wollheim, Gabrielle Kornmann, Dorina Bischof, Margaretha Stam Moraga, Brian Hennessy & Enrica Alteri, 2011, In: Multiple Sclerosis Journal. 17, 4, p. 431-440

    Research output: Contribution to journalArticle

  17. 2009
  18. Impact of cumulative dose and time on magnetic resonance imaging and clinical outcomes during long-term treatment with subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: exploratory analyses

    A. Traboulsee, C. Constantinescu, L. Kappos, D. Ll, M. Sandberg, B. Uitdehaag, J. Gardner & E. Verdun, 2009, In: Multiple Sclerosis Journal. 15, 9, p. S126-S127

    Research output: Contribution to journalPublished meeting abstract

  19. Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis

    N. Mattsson, M. Axelsson, S. Haghighi, C. Malmestrom, G. Wu, R. Anckarsater, S. Sankaranarayanan, U. Andreasson, S. Fredrikson, A. Gundersen, L. Johnsen, T. Fladby, A. Tarkowski, E. Trysberg, A. Wallin, Henrik Anckarsäter, J. Lycke, O. Andersen, A. J. Simon, K. Blennow & 1 others, H. Zetterberg, 2009, In: Multiple Sclerosis Journal. 15, 4, p. 448-454

    Research output: Contribution to journalArticle

  20. The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions.

    Gisela Kobelt, B Texier-Richard & P Lindgren, 2009, In: Multiple Sclerosis Journal. 15, p. 741-751

    Research output: Contribution to journalArticle

  21. 2008
  22. Cognitive dysfunction 24-31 years after isolated optic neuritis.

    Petra Nilsson, Ia Rorsman, E M Larsson, Bo Norrving & Magnhild Sandberg Wollheim, 2008, In: Multiple Sclerosis Journal. 14, p. 913-918

    Research output: Contribution to journalArticle

  23. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.

    Gisela Kobelt, Johan Berglund, P Lindgren, B Jonsson, L Stawiarz & J Hillert, 2008, In: Multiple Sclerosis Journal. 14, 5, p. 679-690

    Research output: Contribution to journalArticle

  24. Nordic trial of methylprednisolone as add-on therapy to interferon-beta for the treatment of relapsing-remitting multiple sclerosis

    Per Soelberg Sorensen, Jette L. Frederiksen, Kjell-Morten Myhr, Antonie Beiske, Svein I. Mellgren & Magnhild Sandberg Wollheim, 2008, In: Multiple Sclerosis Journal. 14, p. S299-S300

    Research output: Contribution to journalPublished meeting abstract

  25. Oral teriflunomide in patients with relapsing multiple sclerosis: baseline clinical features of patients in the TEMSO phase III trial

    Paul O'Connor, Christian Confavreux, Giancarlo Comi, Ludwig Kappos, Jerry Wolinsky, Tomas Olsson, Aaron Miller & Mark S. Freedman, 2008, In: Multiple Sclerosis Journal. 14, p. S85-S85

    Research output: Contribution to journalPublished meeting abstract

  26. 2007
  27. A follow-up study of Nordic multiple sclerosis candidate gene regions

    P. Datta, H. F. Harbo, L. P. Ryder, E. Akesson, J. Benedikz, E. G. Celius, O. Andersen, K-M Myhe, Magnhild Sandberg Wollheim, J. Hillert, A. Svejgaard, P. S. Sorensen, A. Spurkland & A. Oturai, 2007, In: Multiple Sclerosis Journal. 13, 5, p. 584-589

    Research output: Contribution to journalArticle

  28. Health-related quality of life in secondary progressive multiple sclerosis

    A. G. Beiske, H. Naess, J. H. Aarseth, O. Andersen, I. Elovaara, M. Farkkila, H. J. Hansen, S. I. Mellgren, Magnhild Sandberg Wollheim, P. S. Sorensen & K. M. Myhr, 2007, In: Multiple Sclerosis Journal. 13, 3, p. 386-392

    Research output: Contribution to journalArticle

  29. 2004
  30. No evidence for genetic linkage between development of multiple sclerosis and components of the IFN system and the JAK-STAT pathway.

    My Bergkvist, M Olsson & Magnhild Sandberg Wollheim, 2004, In: Multiple Sclerosis Journal. 10, 1, p. 87-88

    Research output: Contribution to journalArticle

  31. 2002
  32. International consensus statement on the use of disease-modifying agents in multiple sclerosis

    MS Freedman, LD Blumhardt, B Brochet, G Comi, JH Noseworthy, Magnhild Sandberg Wollheim & PS Sorensen, 2002, In: Multiple Sclerosis Journal. 8, 1, p. 19-23

    Research output: Contribution to journalArticle